Latest News | Aurobindo Pharma Gets VAI Classification from USFDA for Telangana Plant

New Delhi, Feb 14 (PTI) Aurobindo Pharma on Tuesday said it has received Voluntary Action Indicated (VAI) from the US health regulator for its Telangana-based manufacturing plant.

As per the information available on the United States Food and Drug Administration (USFDA) website, the company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated (VAI), the drug maker said in a regulatory filing.

Also Read | Jharkhand Horror: Lovelorn Girl Meets Tragic End Ahead of Valentine's Day, Lover Rapes and Kills Her by Inserting Iron Rod in Private Parts.

The USFDA had inspected the site from November 10 to November 18, 2022.

As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Also Read | WPI Inflation Eases to 2-Year Low of 4.73% in January 2023; Food Items Turned Expensive.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)